MétaCan
Menu
Back to cohort
Record W2108132938

Protocole de désensibilisation dans le cas d’une allergie au méthotrexate utilisé à hautes doses

2013· article· fr· W2108132938 on OpenAlexaff
Marie‐Élaine Métras, Audrey Marchildon Juneau, Caroline Ruel

Bibliographic record

Venuenot available
Typearticle
Languagefr
FieldMedicine
TopicChemotherapy-related skin toxicity
Canadian institutionsUniversité de Montréal
Fundersnot available
KeywordsMedicineGynecologyMethotrexateSurgery
DOInot available

Abstract

fetched live from OpenAlex

Resume Objectif : Illustrer le cas d’un patient ayant presente une reaction allergique importante au methotrexate utilise a hautes doses et detailler la prise en charge medicale effectuee pour poursuivre ce traitement de premier recours en vue de soigner son osteosarcome. Resume du cas : Le cas presente est celui d’un patient âge de 14 ans atteint d’un osteosarcome du femur distal droit avec des metastases pulmonaires. Le traitement qu’il recoit est un protocole du Children Oncology Group, le AOST0331, qui inclut l’administration de methotrexate a une dose de 12 g/m2. Lors de la perfusion de la premiere dose de methotrexate, il a presente une reaction allergique importante. Une reaction similaire s’est produite lors de la deuxieme dose malgre l’administration de premedication. Une allergie au methotrexate a donc ete constatee, et un protocole de desensibilisation a du etre elabore pour pouvoir poursuivre le traitement. Discussion : Peu de rapports de cas d’allergie au methotrexate sont disponibles dans la litterature medicale. Les strategies employees dans ces cas sont variees : administration de premedication, administration de doses croissantes ou augmentation du temps de perfusion du methotrexate. Ces donnees limitees n’ont pas permis l’elaboration d’un consensus sur la conduite a adopter dans ces situations. Conclusion : La strategie de desensibilisation qui a ete adoptee pour ce patient semble avoir ete efficace et lui a permis de recevoir le traitement de methotrexate au complet. Abstract Objective: To discuss a patient presenting with an important allergic reaction to high-dose methotrexate and to outline medical management to continue first-line treatment for osteosarcoma. Case summary: A 14-year old patient with osteosarcoma of the right distal femur with lung metastases was admitted to the hospital. The treatment received was AOST0331 protocol from the Children’s Oncology Group which included the administration of methotrexate at a dose of 12 g/m2. The patient had a significant allergic reaction during the infusion of the first dose of methotrexate. A similar reaction occurred during the second dose despite the use of premedication. An allergy to methotrexate was confirmed and a desensitization protocol was developed. Discussion: Few case reports of allergic reactions to methotrexate have been reported in the literature. In these cases, different approaches have been used, including the administration of pre-medications, administering increasing doses, or increasing the length of the infusion of methotrexate. Conclusion: Desensitization strategy used for this patient was effective, thus allowing the patient to receive his complete course of methotrexate. Key words: Allergy, anaphylaxis, desensitization, methotrexate, osteosarcoma

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.021
metaresearch head score (Gemma)0.034
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.025
Threshold uncertainty score0.113

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0210.034
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0020.002
Open science0.0020.001
Research integrity0.0030.004
Insufficient payload (model declined to judge)0.0250.006

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.286
Teacher spread0.267 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2013
Admission routes1
Has abstractyes

Explore more

Same topicChemotherapy-related skin toxicityFrench-language works237,207